Business Context and Reporting Period
Company: LeonaBio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 26, 2026
Principal Executive Offices: Bothell, WA
Trading Symbol: LONA (Nasdaq Capital Market)
Key Financial Metrics
This filing does not report standard financial metrics such as revenue, profit, cash flow, margins, or debt levels. The document focuses on a specific corporate event and potential capital raise.
- Potential Capital Raise: Approximately $146.2 million if Series A Common Warrants are exercised in full.
- Warrant Exercise Price: $6.35 per share (cash or cashless net exercise).
- Warrant Quantity: 23,031,494 Series A Common Warrants issued in December 2025.
Material Changes and Events
Clinical Trial Milestone: The Company announced the enrollment of the 500th subject in its Phase 3 ELAINE-3 clinical trial (NCT05696626). This trial evaluates lasofoxifene in combination with abemaciclib for ER+, HER2-negative, ESR1-mutated metastatic breast cancer.
Warrant Exercise Trigger: The enrollment of the 500th subject established the "ELAINE-3 Enrollment Date." Consequently, the Series A Common Warrants became exercisable on August 26, 2026, as this date preceded the June 30, 2026, and October 31, 2026, thresholds defined in the warrant agreement.
Exercise Window: The warrants are exercisable until the 30th day following the initial exercise date, with a termination date no later than November 30, 2026.
Guidance, Outlook, and Risks
Management Commentary: The filing serves as the public announcement required to trigger the warrant exercise period. Management highlights the potential for $146.2 million in additional capital but notes this is contingent on holder action.
Risks and Contingencies:
- Exercise Uncertainty: Warrants may expire unexercised or be exercised on a cashless net basis, resulting in less or no cash proceeds.
- Clinical and Regulatory Risks: Enrollment, data, or regulatory outcomes for the ELAINE-3 Trial or third-party products (e.g., imlunestrant) may differ from expectations.
- Forward-Looking Statements: The Company disclaims any obligation to update forward-looking statements regarding proceeds or trial outcomes.
Investor Verification Checklist
- Verify the actual exercise activity of the 23,031,494 Series A Common Warrants between August 26, 2026, and November 30, 2026.
- Confirm whether warrant exercises are conducted via cash or cashless net exercise to determine actual capital inflow.
- Monitor subsequent filings for updates on the ELAINE-3 Trial data readout and regulatory interactions.
- Review the Company's most recent 10-K or 10-Q for current cash position and liquidity status, as this 8-K does not provide those figures.